Sirona Biochem (Seite 793)
eröffnet am 23.06.13 12:55:10 von
neuester Beitrag 08.05.24 17:10:08 von
neuester Beitrag 08.05.24 17:10:08 von
Beiträge: 31.047
ID: 1.183.167
ID: 1.183.167
Aufrufe heute: 56
Gesamt: 5.404.049
Gesamt: 5.404.049
Aktive User: 0
ISIN: CA82967M1005 · WKN: A0RM6R · Symbol: ZSB
0,0460
EUR
0,00 %
0,0000 EUR
Letzter Kurs 10.05.24 Tradegate
Neuigkeiten
07.05.24 · IRW Press |
07.05.24 · globenewswire  |
08.04.24 · globenewswire |
05.04.24 · globenewswire |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 8,2570 | +96,67 | |
| 17,440 | +44,61 | |
| 1,9750 | +27,42 | |
| 1,8400 | +26,03 | |
| 4,0000 | +25,00 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,7275 | -18,72 | |
| 0,7100 | -19,32 | |
| 0,5350 | -20,15 | |
| 3,0800 | -23,76 | |
| 3,0740 | -77,41 |
Beitrag zu dieser Diskussion schreiben
Feedback
Sirona Biochem Releases CEO Letter to Shareholders
Vancouver, British Columbia – November 30, 2020 – Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (US-OTC: SRBCF) (“Sirona”) is pleased to provide an update from the Company’s CEO, Dr. Howard Verrico.
Dear Shareholders,
This year, we decided to provide our investor community with a FAQ format as an update on some of the progress and activities currently underway at Sirona.
Q: Will we have any news before the end of 2020?
Sirona’s projected milestones will occur within the next 7 months. As per our Investor PowerPoint, we have provided a list of items we feel are within our control and our goal remains to announce them within that timeframe. Estimating timelines is difficult for two reasons. One is that many of our milestones rely on partner organizations and we cannot control their progress or what they choose to make public, and two, research and development can often take unexpected pathways. There are times when we need to switch strategies based on results and/or resources available, but our decisions are always in the best interest of increasing shareholder value. While we do our best to estimate project outcomes and timelines, they are based on variable factors and can change without notice.
Q: In your interview with Smallcap-Investor, you said there would be news in early 2020 from Wanbang. Is this still expected?
The Wanbang trial was delayed due to COVID-19 early in the pandemic. The delay was relatively brief as the infections were quickly brought under control, but it did have an impact on the timing of the studies. Wanbang have restarted and we have been informed that the trial is currently meeting expectations of efficacy and safety. Wanbang is in full control of publicly released information on their trials and advancement of the SGLT2 inhibitor. When they choose to announce, we will immediately inform our investors. If they reach a milestone which triggers a payment to Sirona, then Sirona can issue an independent release as required by stock exchange rules. Consultation with Wanbang would always be part of the process as we maintain our excellent working relationship.
Q: What is happening with the Huaxi deal?
We have been actively performing due diligence on Huaxi with the assistance of Sirona’s consultants on the ground in China. We have found that Huaxi has experienced internal delays so, in parallel, we have decided to talk to other potential partners in China. Over the past month, we have executed several confidentiality agreements and begun introductory meetings as well as due diligence. Huaxi may still procced or the company may become a participant in a larger group. The interest in Sirona and TFC-1067 remains high. We must spend the time and effort to secure the right partner. China is too important to make a strategic misstep with a partner in an effort to rush the product to market. We will secure the right group or groups to move this forward.
Q: What is happening with the Tinyi deal? Will they still be our distribution partner in China?
Tinyi is still expecting to be a distribution partner for TFC-1067 in China. They are also potentially looking to be part of a larger transaction. As in the above response, Sirona is ideally looking for an integrated team based in China to manage all aspects of commercialization. We are actively moving toward this plan with the due diligence of several competent partner groups. This will maximize our growth potential and free up resources to expand into other countries. This aligns with Sirona’s business model to partner and licence our technology with leading industry companies that have established abilities in all aspects of commercialization including manufacturing, regulatory, distribution and sales in local markets around the world. Sirona will grow by doing what it does best, innovation of new cosmetic and therapeutic agents using its proven platform technology.
Q: How long will it take to get CFDA approval for TFC-1067?
We anticipate updates on this issue as regulations are undergoing a major reform. This is something we are planning for our partner to manage but are also actively talking to leading experts on the regulatory landscape.
Q: Why is the Rodan + Fields launch taking so long?
Rodan + Fields spend a great deal of time preparing the introduction of their products and regimes. They are strong advocates of good science and take the necessary time to complete compound studies, formulations, and appropriate marketing analyses. The launch date for TFC-1067 was established early in the program and R+F have not altered that date. We have been informed last week that they are still on track for the scheduled launch. Our established manufacturing will ensure that enough product will be produced to meet the demand for TFC-1067 without delays.
Q: Is the antiviral program on hold?
The antiviral program is not formally on hold, but resources have been temporarily shifted to the anti-aging program as the team in France works on testing various compounds in the library. We have had good results that require further investigation and we felt that shifting the strategy to this program made sense for now. We are actively seeking partnerships while we confirm results. We have new anti-aging compounds which we believe are even more commercially promising both in ease of manufacturing as well as effectiveness. Testing of these new compounds became a priority to secure the patents.
Q: Has COVID-19 had an impact on deal progress?
Yes. COVID-19 has not impacted our ability to work internally but has impacted the ability of our team to travel. Much of our business in China traditionally relies on face-to-face meetings that simply cannot take place so we have adapted. Fortunately, we do have consultants in China who are able to progress our business development. We will resume travel as soon as possible but will not delay business development in the meantime.
Q: What is happening with the diabetic therapy for animals?
Our partner completed extensive due diligence that went beyond the initially set timeline. They have reported to us they are at the very final stages of that process and will be moving to the next level of engagement. We expect an update on this project soon, however, we caution that due to holidays, we cannot be certain that news will be released prior to year-end.
Q: Is Sirona going to improve investor communications?
We are actively working to improve communications. This FAQ sheet is part of that process. You will see more changes over the next few months as we work to keep our shareholders informed of our latest developments. This includes a stronger social media presence and quarterly shareholder updates.
Vancouver, British Columbia – November 30, 2020 – Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (US-OTC: SRBCF) (“Sirona”) is pleased to provide an update from the Company’s CEO, Dr. Howard Verrico.
Dear Shareholders,
This year, we decided to provide our investor community with a FAQ format as an update on some of the progress and activities currently underway at Sirona.
Q: Will we have any news before the end of 2020?
Sirona’s projected milestones will occur within the next 7 months. As per our Investor PowerPoint, we have provided a list of items we feel are within our control and our goal remains to announce them within that timeframe. Estimating timelines is difficult for two reasons. One is that many of our milestones rely on partner organizations and we cannot control their progress or what they choose to make public, and two, research and development can often take unexpected pathways. There are times when we need to switch strategies based on results and/or resources available, but our decisions are always in the best interest of increasing shareholder value. While we do our best to estimate project outcomes and timelines, they are based on variable factors and can change without notice.
Q: In your interview with Smallcap-Investor, you said there would be news in early 2020 from Wanbang. Is this still expected?
The Wanbang trial was delayed due to COVID-19 early in the pandemic. The delay was relatively brief as the infections were quickly brought under control, but it did have an impact on the timing of the studies. Wanbang have restarted and we have been informed that the trial is currently meeting expectations of efficacy and safety. Wanbang is in full control of publicly released information on their trials and advancement of the SGLT2 inhibitor. When they choose to announce, we will immediately inform our investors. If they reach a milestone which triggers a payment to Sirona, then Sirona can issue an independent release as required by stock exchange rules. Consultation with Wanbang would always be part of the process as we maintain our excellent working relationship.
Q: What is happening with the Huaxi deal?
We have been actively performing due diligence on Huaxi with the assistance of Sirona’s consultants on the ground in China. We have found that Huaxi has experienced internal delays so, in parallel, we have decided to talk to other potential partners in China. Over the past month, we have executed several confidentiality agreements and begun introductory meetings as well as due diligence. Huaxi may still procced or the company may become a participant in a larger group. The interest in Sirona and TFC-1067 remains high. We must spend the time and effort to secure the right partner. China is too important to make a strategic misstep with a partner in an effort to rush the product to market. We will secure the right group or groups to move this forward.
Q: What is happening with the Tinyi deal? Will they still be our distribution partner in China?
Tinyi is still expecting to be a distribution partner for TFC-1067 in China. They are also potentially looking to be part of a larger transaction. As in the above response, Sirona is ideally looking for an integrated team based in China to manage all aspects of commercialization. We are actively moving toward this plan with the due diligence of several competent partner groups. This will maximize our growth potential and free up resources to expand into other countries. This aligns with Sirona’s business model to partner and licence our technology with leading industry companies that have established abilities in all aspects of commercialization including manufacturing, regulatory, distribution and sales in local markets around the world. Sirona will grow by doing what it does best, innovation of new cosmetic and therapeutic agents using its proven platform technology.
Q: How long will it take to get CFDA approval for TFC-1067?
We anticipate updates on this issue as regulations are undergoing a major reform. This is something we are planning for our partner to manage but are also actively talking to leading experts on the regulatory landscape.
Q: Why is the Rodan + Fields launch taking so long?
Rodan + Fields spend a great deal of time preparing the introduction of their products and regimes. They are strong advocates of good science and take the necessary time to complete compound studies, formulations, and appropriate marketing analyses. The launch date for TFC-1067 was established early in the program and R+F have not altered that date. We have been informed last week that they are still on track for the scheduled launch. Our established manufacturing will ensure that enough product will be produced to meet the demand for TFC-1067 without delays.
Q: Is the antiviral program on hold?
The antiviral program is not formally on hold, but resources have been temporarily shifted to the anti-aging program as the team in France works on testing various compounds in the library. We have had good results that require further investigation and we felt that shifting the strategy to this program made sense for now. We are actively seeking partnerships while we confirm results. We have new anti-aging compounds which we believe are even more commercially promising both in ease of manufacturing as well as effectiveness. Testing of these new compounds became a priority to secure the patents.
Q: Has COVID-19 had an impact on deal progress?
Yes. COVID-19 has not impacted our ability to work internally but has impacted the ability of our team to travel. Much of our business in China traditionally relies on face-to-face meetings that simply cannot take place so we have adapted. Fortunately, we do have consultants in China who are able to progress our business development. We will resume travel as soon as possible but will not delay business development in the meantime.
Q: What is happening with the diabetic therapy for animals?
Our partner completed extensive due diligence that went beyond the initially set timeline. They have reported to us they are at the very final stages of that process and will be moving to the next level of engagement. We expect an update on this project soon, however, we caution that due to holidays, we cannot be certain that news will be released prior to year-end.
Q: Is Sirona going to improve investor communications?
We are actively working to improve communications. This FAQ sheet is part of that process. You will see more changes over the next few months as we work to keep our shareholders informed of our latest developments. This includes a stronger social media presence and quarterly shareholder updates.
!
Dieser Beitrag wurde von CloudMOD moderiert. Grund: unnötige Provokation, persönliche Angriffe bitte unterlassen
Antwort auf Beitrag Nr.: 65.868.648 von Ulfred am 27.11.20 17:54:02
-100%
Zitat von Ulfred: Kein Grund für Aufregung, am Ende kommen wir alle mit verdienten 100% raus.
-100%
Antwort auf Beitrag Nr.: 65.868.648 von Ulfred am 27.11.20 17:54:02
Warum nicht, wer darauf spekuliert, viele haben 200Prozent und mehr mitgenommen...
mdn
Zitat von Ulfred: Kein Grund für Aufregung, am Ende kommen wir alle mit verdienten 100% raus.
Warum nicht, wer darauf spekuliert, viele haben 200Prozent und mehr mitgenommen...
mdn
Trading Spotlight
Antwort auf Beitrag Nr.: 65.868.648 von Ulfred am 27.11.20 17:54:02Ich hoffe das auch aber ich habe absolut kein Vertrauen mehr.
Kein Grund für Aufregung, am Ende kommen wir alle mit verdienten 100% raus. 
Antwort auf Beitrag Nr.: 65.865.246 von mac_x am 27.11.20 14:06:36Stimmt wie sind so richtig schön verarscht worden vom Vorstand. ES WIRD NOCH VIEL KOMMEN IM LETZTEN QUARTAL Hahaha Danke und LG nach Kanada
2020 kann man komplett vergessen, der SP ist eine einzige Enttäuschung für Sirona-Aktionäre.
DENNOCH; HIER IST ALLES NOCH INTAKT WAS TIMELINES UND ZIELE ANGEHT. WIR HABEN MIT UMSÄTZEN / VERMARKTUNG DURCH R+F IN 2020 GERECHNET. DIES IST AUSGEBLIEBEN, SOLLTE ABER 2021 DEFINITIV DER FALL SEIN!!!
Bin noch mit mickrigen 2,3% im Plus. Nicht realisierte Gewinne tun schon richtig weh! Wenn wir unter 0,10 € fallen sollten, werde ich dankbar sein und nochmal ordentlich zulangen...
DENNOCH; HIER IST ALLES NOCH INTAKT WAS TIMELINES UND ZIELE ANGEHT. WIR HABEN MIT UMSÄTZEN / VERMARKTUNG DURCH R+F IN 2020 GERECHNET. DIES IST AUSGEBLIEBEN, SOLLTE ABER 2021 DEFINITIV DER FALL SEIN!!!
Bin noch mit mickrigen 2,3% im Plus. Nicht realisierte Gewinne tun schon richtig weh! Wenn wir unter 0,10 € fallen sollten, werde ich dankbar sein und nochmal ordentlich zulangen...
Antwort auf Beitrag Nr.: 65.821.713 von Paddy88HH am 24.11.20 12:11:06
dass wir nochmals einstellige Kurse sehen, bezweifle ich... würde aber definitiv zum 2020 passen!
Hoffen wir, dass uns Sirona überrascht.
Es wird Zeit ▶️.
Zitat von Paddy88HH: Also ich muss echt sagen, irgendwie ist das Traurig hier... Ich hoffe sehr, dass im Frühjahr positive impulse kommen mit dem Pharma unternehmen.
Beim Rest.. keine Ahnung.
Zukaufen werde ich wohl nicht mehr. Es kommt dafür einfach zu wenig.
Mit dem Verbot von Hydroquinone in den USA hatte ich ehrlich gesagt einen news ticker erwartet... täglich etwas wie: Interesse hier, Tests und bemusterung da, Absatz... absatz.. absatz.
Aber aktuell dümpelt R+F da nur rum.
Meine aktuelle befürchung ist, dass sich das eben nicht so vermarkten lässt wie angekündigt.
Die wirkung eben nur absolut spezifisch ist und entsprechend nur für eine sehr limitierte Anwendung geeignet ist.
Und der Deal von R+F der nun wirklich(soweit bekannt) unterirdisch ist, scheint nicht wirklich als Sprungbrett zu fungieren.
Die Illusion die aufgebaut wurde verpufft Stück für Stück.
Ich halte es wahrscheinleich, dass wir noch einstellige Kurse sehen werden.
Sollte Sirona Liefern und es kommt ein Produkt und es kommen deals die richtig Geld in die Kassenspülen siehts anders aus. Aber eben nur sollte...
Und das so gar nichts kommt vom Management.... puh.
dass wir nochmals einstellige Kurse sehen, bezweifle ich... würde aber definitiv zum 2020 passen!
Hoffen wir, dass uns Sirona überrascht.
Es wird Zeit ▶️.
Durchsuchen
Sirona Biochem
